Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?

Mohamed Bouattour, Benoît Rousseau, Johanna Wassermann, Audrey Payancé, Olivier Huillard
  • Journal of Clinical Oncology, August 2015, American Society of Clinical Oncology (ASCO)
  • DOI: 10.1200/jco.2014.60.6954
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Dr Mohamed Bouattour